Osteonecrosis of the jaw in patients treated with denosumab for metastatic tumors to the bone: A series of thirteen patients

被引：18

作者：

Owosho, Adepitan A. ^{[1
]}

Blanchard, Ariel ^{[1
]}

Levi, Lauren ^{[1
]}

Kadempour, Arvin ^{[1
]}

Rosenberg, Haley ^{[1
]}

Yom, SaeHee K. ^{[1
]}

Farooki, Azeez ^{[2
]}

Fornier, Monica ^{[2
]}

Huryn, Joseph M. ^{[1
]}

Estilo, Cherry L. ^{[1
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10065 USA

[2] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10065 USA

来源：

JOURNAL OF CRANIO-MAXILLOFACIAL SURGERY | 2016年 / 44卷 / 03期

关键词：

Denosumab; Osteonecrosis of the jaw; Metastatic bone disease; BISPHOSPHONATE-RELATED OSTEONECROSIS; MEDICATION-RELATED OSTEONECROSIS; SKELETAL-RELATED EVENTS; ZOLEDRONIC ACID; BREAST-CANCER; RISK-FACTORS; MULTIPLE-MYELOMA; COST-EFFECTIVENESS; PROSTATE-CANCER; DOUBLE-BLIND;

D O I：

10.1016/j.jcms.2015.12.005

中图分类号：

R78 [口腔科学];

学科分类号：

1003 ;

摘要：

This case series describes the course of osteonecrosis of the jaw (ONJ) in thirteen patients with metastatic bone tumors treated solely with denosumab. Patients on denosumab may be more prone to developing ONJ even without a risk/precipitating factor and they may develop ONJ early in their denosumab therapy. The outcomes of ONJ in ten patients following a period of denosumab discontinuation after the onset of ONJ were: 3 had complete resolution of symptoms, 4 patients' ONJ progressed, 2 patients' ONJ was unchanged and in 1 patient there was partial ONJ resolution. The role of drug discontinuation prior to an invasive dental procedure or after the onset of ONJ still remains debatable. (C) 2015 European Association for Cranio-Maxillo-Facial Surgery. Published by Elsevier Ltd. All rights reserved.

引用

页码：265 / 270

页数：6

共 60 条

[31] Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone Metastases [J].

Lipton, Allan ;

Steger, Guenther G. ;

Figueroa, Jazmin ;

Alvarado, Cristina ;

Solal-Celigny, Philippe ;

Body, Jean-Jacques ;

de Boer, Richard ;

Berardi, Rossana ;

Gascon, Pere ;

Tonkin, Katia S. ;

Coleman, Robert ;

Paterson, Alexander H. G. ;

Peterson, Mark C. ;

Fan, Michelle ;

Kinsey, Amy ;

Jun, Susie .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (28) :4431-4437

[32] Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials [J].

Lipton, Allan ;

Fizazi, Karim ;

Stopeck, Alison T. ;

Henry, David H. ;

Brown, Janet E. ;

Yardley, Denise A. ;

Richardson, Gary E. ;

Siena, Salvatore ;

Maroto, Pablo ;

Clemens, Michael ;

Bilynskyy, Boris ;

Charu, Veena ;

Beuzeboc, Philippe ;

Rader, Michael ;

Viniegra, Maria ;

Saad, Fred ;

Ke, Chunlei ;

Braun, Ada ;

Jun, Susie .

EUROPEAN JOURNAL OF CANCER, 2012, 48 (16) :3082-3092

[33] The relationship of denosumab pharmacology and osteonecrosis of the jaws [J].

Malan, John ;

Ettinger, Kyle ;

Naumann, Erich ;

Beirne, O. Ross .

ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY, 2012, 114 (06) :671-676

[34] Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treatment [J].

Marx, RE ;

Sawatari, Y ;

Fortin, M ;

Broumand, V .

JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, 2005, 63 (11) :1567-1575

[35] Genomewide Pharmacogenetics of Bisphosphonate-Induced Osteonecrosis of the Jaw: The Role of RBMS3 [J].

Nicoletti, Paola ;

Cartsos, Vassiliki M. ;

Palaska, Penelope K. ;

Shen, Yufeng ;

Floratos, Aris ;

Zavras, Athanasios I. .

ONCOLOGIST, 2012, 17 (02) :279-287

[36] Denosumab and osteonecrosis of the jaws - the pharmacology, pathogenesis and a report of two cases [J].

O'Halloran, M. ;

Boyd, N. M. ;

Smith, A. .

AUSTRALIAN DENTAL JOURNAL, 2014, 59 (04) :516-519

[37] Healing of osteonecrosis of the jaw (ONJ) after discontinuation of denosumab in a patient with bone metastases of colorectal cancer: A case report and hypothesis [J].

Ohga, Noritaka ;

Yamazaki, Yutaka ;

Tsuboi, Kanako ;

Kitagawa, Yoshimasa .

QUINTESSENCE INTERNATIONAL, 2015, 46 (07) :621-626

[38]

Olate S, 2014, INT J CLIN EXP MED, V7, P3707

[39] Successful surgical management of osteonecrosis of the jaw due to RANK-ligand inhibitor treatment using fluorescence guided bone resection [J].

Otto, Sven ;

Baumann, Sebastian ;

Ehrenfeld, Michael ;

Pautke, Christoph .

JOURNAL OF CRANIO-MAXILLOFACIAL SURGERY, 2013, 41 (07) :694-698

[40] Osteonecrosis of the jaw a new complication related to Ipilimumab [J].

Owosho, Adepitan A. ;

Scordo, Michael ;

Yom, SaeHee K. ;

Randazzo, Joseph ;

Chapman, Paul B. ;

Huryn, Joseph M. ;

Estilo, Cherry L. .

ORAL ONCOLOGY, 2015, 51 (12) :E100-E101

← 1 2 3 4 5 6 →